Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Impact · against what's priced in

Enliven Therapeutics significantly strengthens its balance sheet by raising $460 million, extending its operational runway and demonstrating strong institutional demand via an upsized offering. While the issuance of over 10.5 million shares causes equity dilution, the massive cash infusion is a net positive for a clinical-stage biotech. The impact on the underwriting banks is negligible as these are routine fee-generating activities.

ELVN+0.40: No priced-in read yet

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

What matters in this story

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

What matters in this story

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

How each ticker is affected

Connected tickers

Track these names every morning.

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

Alphabet's 2 Classes of Common Stock Trade About 1% Apart. Here's the One I'd Buy.

Biotech stocks are surging. How investors can play the new drug innovation boom

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

What matters in this story

Next reads from the same story arc

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

What matters in this story

Next reads from the same story arc

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

How each ticker is affected

Connected tickers

Track these names every morning.

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

Alphabet's 2 Classes of Common Stock Trade About 1% Apart. Here's the One I'd Buy.

Biotech stocks are surging. How investors can play the new drug innovation boom

Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors